Jessica R Allegretti1, Dina Kao2, Emmalee Phelps3, Brandi Roach2, Justin Smith2, Vincent C Ganapini3, Zain Kassam4, Huiping Xu5, Monika Fischer3. 1. Division of Gastroenterology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. jallegretti@bwh.harvard.edu. 2. Division of Gastroenterology, Zeidler Ledcor Centre, University of Alberta, Edmonton, AB, Canada. 3. Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, IN, USA. 4. Finch Therapeutics Group, Somerville, USA. 5. Department of Biostatistics, The Richard M. Fairbanks School of Public Health and School of Medicine, Indiana University, Indianapolis, IN, USA.
Abstract
INTRODUCTION: The risk of a new Clostridium difficile infection (CDI) after FMT is unknown if non-CDI antibiotics are required. It is uncertain if anti-CDI prophylaxis or probiotics would reduce risk. We therefore aimed to compare the risk of CDI with and without antibiotic exposure and the benefit of concomitant anti-CDI antibiotic or probiotic prophylaxis. METHODS: This is a multicenter retrospective study carried out at three large FMT referral centers of patients who underwent FMT for recurrent CDI. Patients were assessed for antibiotic use, as well as concomitant use of prophylactic anti-CDI antibiotics or probiotics. Time to CDI recurrence after FMT was evaluated using the Kaplan-Meier method. RESULTS: A total of 404 patients were included: 63% were females, with a mean age of 61.3 ± 18.8 years. Mean length of post-FMT follow-up was 18.1 ± 11.9 months (range 2.2-45.2). Among the entire cohort 8.1% (n = 33) experienced a CDI recurrence. Overall, 111 patients (27.4%) used a non-CDI antibiotic, of which 16.2% (n = 18) experienced a CDI recurrence. Patients who used non-CDI antibiotics were more likely to develop CDI (HR 8.44, 95% CI 4.21-16.93, p < 0.001). The risk of CDI recurrence was not different between patients who received anti-CDI antibiotic prophylaxis to those who did not (HR = 1.88, 95% CI 0.72-4.86, p = 0.2); however, probiotic prophylaxis was associated with a greater risk of CDI recurrence (HR = 2.65, 95% CI 1.02-6.86, p = 0.045). CONCLUSION: Non-CDI antibiotic use was not uncommon after successful FMT and significantly increased the risk of a new episode of CDI. In this study, we found that the prophylactic use of anti-CDI antibiotics or probiotics was not protective.
INTRODUCTION: The risk of a new Clostridium difficileinfection (CDI) after FMT is unknown if non-CDI antibiotics are required. It is uncertain if anti-CDI prophylaxis or probiotics would reduce risk. We therefore aimed to compare the risk of CDI with and without antibiotic exposure and the benefit of concomitant anti-CDI antibiotic or probiotic prophylaxis. METHODS: This is a multicenter retrospective study carried out at three large FMT referral centers of patients who underwent FMT for recurrent CDI. Patients were assessed for antibiotic use, as well as concomitant use of prophylactic anti-CDI antibiotics or probiotics. Time to CDI recurrence after FMT was evaluated using the Kaplan-Meier method. RESULTS: A total of 404 patients were included: 63% were females, with a mean age of 61.3 ± 18.8 years. Mean length of post-FMT follow-up was 18.1 ± 11.9 months (range 2.2-45.2). Among the entire cohort 8.1% (n = 33) experienced a CDI recurrence. Overall, 111 patients (27.4%) used a non-CDI antibiotic, of which 16.2% (n = 18) experienced a CDI recurrence. Patients who used non-CDI antibiotics were more likely to develop CDI (HR 8.44, 95% CI 4.21-16.93, p < 0.001). The risk of CDI recurrence was not different between patients who received anti-CDI antibiotic prophylaxis to those who did not (HR = 1.88, 95% CI 0.72-4.86, p = 0.2); however, probiotic prophylaxis was associated with a greater risk of CDI recurrence (HR = 2.65, 95% CI 1.02-6.86, p = 0.045). CONCLUSION: Non-CDI antibiotic use was not uncommon after successful FMT and significantly increased the risk of a new episode of CDI. In this study, we found that the prophylactic use of anti-CDI antibiotics or probiotics was not protective.
Authors: Nicole T Shen; Anna Maw; Lyubov L Tmanova; Alejandro Pino; Kayley Ancy; Carl V Crawford; Matthew S Simon; Arthur T Evans Journal: Gastroenterology Date: 2017-02-10 Impact factor: 22.682
Authors: M J T Crobach; T Planche; C Eckert; F Barbut; E M Terveer; O M Dekkers; M H Wilcox; E J Kuijper Journal: Clin Microbiol Infect Date: 2016-07-25 Impact factor: 8.067
Authors: L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox Journal: Clin Infect Dis Date: 2018-03-19 Impact factor: 9.079
Authors: Giovanni Cammarota; Gianluca Ianiro; Herbert Tilg; Mirjana Rajilić-Stojanović; Patrizia Kump; Reetta Satokari; Harry Sokol; Perttu Arkkila; Cristina Pintus; Ailsa Hart; Jonathan Segal; Marina Aloi; Luca Masucci; Antonio Molinaro; Franco Scaldaferri; Giovanni Gasbarrini; Antonio Lopez-Sanroman; Alexander Link; Pieter de Groot; Willem M de Vos; Christoph Högenauer; Peter Malfertheiner; Eero Mattila; Tomica Milosavljević; Max Nieuwdorp; Maurizio Sanguinetti; Magnus Simren; Antonio Gasbarrini Journal: Gut Date: 2017-01-13 Impact factor: 23.059
Authors: Alexander Khoruts; Michael J Sadowsky; Christopher Staley; Thomas Kaiser; Byron P Vaughn; Carolyn Graiziger; Matthew J Hamilton; Amanda J Kabage Journal: mBio Date: 2019-07-23 Impact factor: 7.867
Authors: Charmaine Normington; Ines B Moura; Jessica A Bryant; Duncan J Ewin; Emma V Clark; Morgan J Kettle; Hannah C Harris; William Spittal; Georgina Davis; Matthew R Henn; Christopher B Ford; Mark H Wilcox; Anthony M Buckley Journal: NPJ Biofilms Microbiomes Date: 2021-02-05 Impact factor: 7.290
Authors: Anne J Gonzales-Luna; Jennifer K Spinler; Numan Oezguen; Md Abdul Wadud Khan; Heather A Danhof; Bradley T Endres; M Jahangir Alam; Khurshida Begum; Chris Lancaster; Gabriela Pd Costa; Tor C Savidge; Julian G Hurdle; Robert Britton; Kevin W Garey Journal: Anaerobe Date: 2021-05-24 Impact factor: 2.837